 | Bioactive-Loaded Nanomedicine for the Management of Health and Disease Subjects: Bioscience; Engineering & Technology; Physical Sciences; Pharmaceutical Science; Nanobiotechnology; Materials Science; Biomaterials; The new book focuses on the use of natural active substances and nutraceuticals in nano-research for improved healthcare management and applications. It explores advanced nanomaterials that can be utilized for the encapsulation of nutrients, vitamins, and phytoconstituents for effective healthcare results. The chapters discuss the apparent remarkable advantages of using new bioactive and nutraceutical drugs compared to conventional plant action formulations and extracts. These new formulations offer improved solubility, bioavailability, simultaneous drug delivery, safety extension, long-term delivery, better dissemination of tissue macrophages, security against toxicity, increase in pharmacological activity, and enhanced physical and chemical protection. With chapters from leading scientists from around the world, this volume highlights these new developments in nano-based medicines for the treatment of cancer, psychotic and manic disorders, and chronic inflammation, such as arthritis and psoriasis, as well as for other healthcare issues, such as skin diseases and skin care, atherosclerosis, and more. A variety of nanoformulations is discussed, including polymeric nanoparticles, nanocapsules, nanoemulsions, transferosomes and ethosomes, liposomes, lipospheres, lipid polymers, hybrid nanoparticles, etc. Key features: Reviews phyto-actives and their targeted action in the management of various cancers Looks at the use of phytochemical-based nano-cosmeceuticals for beautification Explores emerging concepts of vitamins and nanocarriers as nutraceuticals Discusses the advantages of bioactive-loaded nanomedicines over conventional phytotherapiesBioactive-Loaded Nanomedicine for the Management of Health and Disease will be of great use and provide insight to phytochemists, nanoscientists, nano-biotechnologists, and others involved in the field of healthcare systems. Mahfoozur Rahman, PhD, is Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. His major areas of research interest include development and characterization of nanosized drug delivery systems for inflammatory disorders including psoriasis, arthritis, neurodegenerative disorders, cancer, etc. In addition, he is also working on amalgamation of herbal medicinal plants with modern therapeutics in order to deliver a scientifically acceptable therapy for various diseases management. To date, he has published over 100 publications in peer-reviewed journals as well as over 20 book chapters, several international books, and several articles in international magazines. Overall, he has earned highly impressive publishing and cited record in Google Scholar (H-index of 26, total citations: 1700). He is also serving as a guest editor of Seminar in Cancer Biology, Recent Patents on Anti-Infective Drug Discovery , and Current Nanomedicine . Dr. Rahman has received travel grants from various international organizations, such as the IAPRD, MDS, Nano Today Conference, KSN 2019 for his best research paper, etc. Sarwar Beg, PhD , is Assistant Professor in the Department of Pharmaceutics, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard (Hamdard University), New Delhi, India. He has nearly a decade of experience in systematic development and characterization of novel and nanostructured drug delivery systems using QbD paradigms, including design of experiments (DoE), and quality risk management (QRM). He has published over 150 review/research articles in peer-reviewed journals, over 45 book chapters, over 12 books, and over 10 journal special issues. He holds three Indian patent applications and has presented at many conferences. Dr. Beg has received many awards, including the SIPRA Innovative Pharma Research Award 2016 and Bronze Medal (by SIPRA Labs, Hyderabad); Eudragit Award 2015 in South Asia (by Evonik GmbH, Germany); Budding QbD Scientist Award 2014 and Budding ADME & Toxicology Scientist Award 2013 (by Select Biosciences, UK); and Novartis Biotechnology Leadership Camp Award 2012 (by Novartis, Hyderabad). He also received a a prestigious Sun Pharma Science Foundation-Young Science Scholar Award for his research contributions in the field of pharmaceutical sciences presented by the Honorable Health Minister of India and Managing Director-Sun Pharmaceutical Industries. Khalid S. Alharbi, PhD , is Assistant Professor in the Department of Pharmacology, College of Pharmacy, Jouf University, Sakakah, Saudi Arabia. Dr. Alharbi''s major area of research is cancer, focusing on drug discovery, nanomedicine, and preclinical pharmacological and toxicological studies of anticancer agents. He has published several articles in peer-reviewed journals and has presented papers at numerous international conferences. He obtained both his BSc (Pharmaceutical Sciences) and MSc (Toxicology) from the College of Pharmacy at King Saud University (KSU), Riyadh, Saudi Arabia. He was awarded his PhD (Pharmacy and Biomedical Sciences) from Stathclyde University, United Kingdom. Waleed Hassan Almalki, PhD , is Professor of Pharmacology at the College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. His current research is focused on the broad areas of host-virus networks in Hepacivirus C disease progression as well as host-virus genes expression during oxidative stress, hepatic steatosis, fibrosis, and hepatocellular carcinoma. He is also enthusiastically involved in the study of tyrosine kinase inhibitors for the treatment of breast and colon cancer. Dr. Waleed has published many research and review articles in peer-reviewed international journals on HCV pathogenesis and treatment and drug designing. He has also edited book chapters on angiogenesis, pharmacological assays, and infectious disease epidemiology. He earned his doctoral degree from the University of Glasgow, United Kingdom, having a dissertation on ocular pharmacology. Nabil K. Alruwaili, PhD , is Assistant Professor in the Pharmaceutics Department at the School of Pharmacy, Jouf University, Sakaka, Saudi Arabia. He is also the Chairman of the Pharmaceutics Department. Previously, Dr. Alruwaili worked at SFDA in product evaluation and standards-setting administration in Riyadh, KSA, where he gained experience in assessment and registration dossiers submitted by companies for a variety of pharmaceutical products. He has several published articles and has presented papers at international and national scientific conferences. He earned both his BSc (Pharmaceutical Sciences) and MSc (Quality Control of Pharmaceutic) degrees from the College of Pharmacy at King Saud University (KSU), Riyadh, Saudi Arabia. He was awarded his PhD (Pharmaceutics) from the Massachusetts College of Pharmacy and Health Sciences, USA. Majed Al Robaian, PhD , is Dean of the Faculty of Pharmacy at Taif University in Saudi Arabia. His research interests focus on drug delivery and, in particular, the delivery of therapeutic genes for the treatment of cancer. Before obtaining his PhD he worked as Director of Pharmacy at King Abdulaziz Hospital. Currently, he the Science Faculty Ambassador for Strathclyde University, UK. He is a member of a number of committees of the Saudi Commission for Health Specialties. He earned his BSc from King Saud University in Riyadh Saudi Arabia, his MSc in Pharmaceutical Sciences from Strathclyde University in the United Kingdom, and his PhD from the same university. |
